Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07122401) titled 'Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism' on Aug. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Condition:
Secondary Hyperparathyroidism, Chronic Kidney Disease
Intervention:
Drug: MT1013
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: September 30, 2025
Target Sample Size: 424
Countries of Recruitme...